3649 results for «414»
3649 results
Calcified left main lesion PCI
05 Jul 2019 – From AICT-AsiaPCR 2019
Consult this session to discover the key clinical data and angiographic reference of a patient presenting with calcified left main lesion PCI.
Complex distal left main bifurcation lesion
04 Jul 2019 – From AICT-AsiaPCR 2019
A 75-year-old male with multiple risk factors and a history of NSTEMI is admitted for staged PCI to his left main bifurcation. His vessels are diffusely calcified…
AICT-AsiaPCR Opening Ceremony
04 Jul 2019 – From AICT-AsiaPCR 2019
Consult this session to watch AICT-AsiaPCR 2019 Opening Ceremony, led by Jean Fajadet. Discover the missions of PCR, and the novelties offered by the AICT-AsiaPCR course, arising from the Asia-Pacific region and showcasing its clinical research and innovations.
LAD/D1 bifurcation disease
06 Jul 2019 – From AICT-AsiaPCR 2019
Consult this session to discover the key clinical data and angiographic reference of a patient presenting with LAD/D1 bifurcation disease.
Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026
27 May 2026
Four-Year Outcomes from the EVOLUT Low Risk Trial
26 Oct 2023
Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)
Author
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial
01 Apr 2025
Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.
Author
